Plasminogen activator inhibitor in the blood of patients with coronary artery disease.
作者信息
Paramo J A, Colucci M, Collen D, van de Werf F
出版信息
Br Med J (Clin Res Ed). 1985 Aug 31;291(6495):573-4. doi: 10.1136/bmj.291.6495.573.
Abstract
摘要
相似文献
1
Plasminogen activator inhibitor in the blood of patients with coronary artery disease.冠状动脉疾病患者血液中的纤溶酶原激活物抑制剂
Br Med J (Clin Res Ed). 1985 Aug 31;291(6495):573-4. doi: 10.1136/bmj.291.6495.573.
2
Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.冠状动脉疾病患者的纤溶酶原激活物抑制剂活性及其他纤溶变量
Br Heart J. 1988 May;59(5):535-41. doi: 10.1136/hrt.59.5.535.
3
Impaired fibrinolysis in coronary artery disease.
Am Heart J. 1988 Apr;115(4):776-80. doi: 10.1016/0002-8703(88)90878-2.
4
5
6
[Changes in plasma tissue plasminogen activator and plasminogen activator inhibitor in acute myocardial infarction and its clinical significance].[急性心肌梗死患者血浆组织型纤溶酶原激活物及纤溶酶原激活物抑制剂的变化及其临床意义]
Zhonghua Xin Xue Guan Bing Za Zhi. 1988 Aug;16(4):214-6, 254.
7
Alterations in plasminogen activator and plasminogen activator inhibitor levels during liver transplantation.肝移植过程中纤溶酶原激活物和纤溶酶原激活物抑制剂水平的变化。
Transplant Proc. 1989 Jun;21(3):3540-1.
8
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
Br J Haematol. 1987 May;66(1):85-9. doi: 10.1111/j.1365-2141.1987.tb06894.x.
9
Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis.深静脉血栓形成患者血液中的纤溶酶原激活物抑制剂（PA抑制剂）活性
Thromb Haemost. 1985 Oct 30;54(3):725.
10
The role of the fibrinolytic system in thrombotic disease.纤溶系统在血栓性疾病中的作用。
Acta Med Scand Suppl. 1987;715:169-71. doi: 10.1111/j.0954-6820.1987.tb09918.x.
引用本文的文献
1
Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease.血栓形成/溶栓平衡作为糖尿病合并冠状动脉疾病患者的心脏治疗决定因素。
J Am Heart Assoc. 2019 Jan 22;8(2):e011207. doi: 10.1161/JAHA.118.011207.
2
A Common Calibrator Does Not Secure Harmonisation of Commercial t-PA and PAI-1 Antigen Measurements.通用校准品无法确保商业组织型纤溶酶原激活剂（t-PA）和纤溶酶原激活物抑制剂-1（PAI-1）抗原检测结果的一致性。
EJIFCC. 2001 Jul 22;13(2):39-47. eCollection 2001 Jul.
3
Evaluation of Fibrinolytic Inhibitors: Alpha-2-Antiplasmin and Plasminogen Activator Inhibitor 1 in Patients with Obstructive Sleep Apnoea.阻塞性睡眠呼吸暂停患者中纤溶酶原激活物抑制剂：α-2-抗纤溶酶和纤溶酶原激活物抑制剂1的评估
PLoS One. 2016 Nov 18;11(11):e0166725. doi: 10.1371/journal.pone.0166725. eCollection 2016.
4
Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.戊酸雌二醇/地诺孕素（一种新型口服避孕药）的代谢和止血作用：一项随机、开放标签、单中心研究。
Clin Drug Investig. 2011;31(8):573-584. doi: 10.2165/11590220-000000000-00000.
5
Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.1型纤溶酶原激活物抑制剂（第一部分）：基本机制、调节及其在血栓栓塞性疾病中的作用
J Thromb Thrombolysis. 2001 May;11(3):183-93. doi: 10.1023/a:1011955018052.
6
Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease.纤溶酶原激活物抑制剂-1的基因多态性与冠状动脉疾病的血管造影范围相关。
J Thromb Thrombolysis. 1998 May;5(2):143-150. doi: 10.1023/A:1008882113177.
7
Potential Antithrombotic and Fibrinolytic Properties of the Angiotensin Converting Enzyme Inhibitors.血管紧张素转换酶抑制剂的潜在抗血栓形成和纤维蛋白溶解特性。
J Thromb Thrombolysis. 1995;1(3):251-257. doi: 10.1007/BF01060734.
8
Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.
J Thromb Thrombolysis. 1994;1(1):35-40. doi: 10.1007/BF01061993.
9
Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?再狭窄中的纤溶酶激活系统：在发病机制及临床预测中的作用？
J Thromb Thrombolysis. 1999 Jun;7(3):277-85. doi: 10.1023/a:1008983110941.
10
Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease.缺血性心脏病男性患者体内组织型纤溶酶原激活物及其抑制剂、血管性血友病因子抗原和前列环素刺激因子的昼夜变化。
Br Heart J. 1993 Feb;69(2):121-4. doi: 10.1136/hrt.69.2.121.
本文引用的文献
1
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.正常和病理状态下组织型纤溶酶原激活物（及尿激酶）特异性抑制剂的血浆水平。
Thromb Res. 1984 Mar 1;33(5):523-30. doi: 10.1016/0049-3848(84)90018-5.
2
Mechanisms of inhibition of tissue-type plasminogen activator in blood.血液中组织型纤溶酶原激活物的抑制机制。
Thromb Haemost. 1983 Oct 31;50(3):678.
3
Fibrinolytic activity and coronary-artery disease.
Lancet. 1968 May 11;1(7550):987-90. doi: 10.1016/s0140-6736(68)91104-5.
4
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.血浆中响应内毒素刺激而产生纤溶酶原激活物的快速作用抑制剂。
J Clin Invest. 1985 Mar;75(3):818-24. doi: 10.1172/JCI111777.
Zotero 插件